Business Wire

First Clinical Study of SeptAlign™ Implant Demonstrates Safety and Efficacy in Treating Nasal Septal Deviation While Preserving Cartilage

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spirair, Inc., an early-stage company developing minimally invasive solutions to help ENTs improve patient care, today announced the publication of the ...
BioWorld

It’s Spirair by a nose as Septalign gains FDA clearance

Spirair Inc. won the race for the first U.S. FDA 510(k) clearance for a minimally invasive therapy for nasal septal deviation (NSD), the company said. The Septalign system features a bioabsorbable ...
Pharmabiz

Spirair receives US FDA clearance for TurbAlign, a new bioabsorbable implant that helps keep nasal passages open after sinus surgery

Spirair, Inc., an early-stage medical device company developing minimally invasive solutions to help ENTs improve patient care, announced that the US Food and Drug Administration (FDA) has granted 510 ...